晚期慢性肾脏病合并脓毒症诱导低血压患者的液体管理:CLOVERS试验的二次分析
该研究为CLOVERS试验的事后分析,纳入晚期CKD(eGFR<30 mL/min/1.73 m2或终末期肾病规律透析)合并脓毒症诱导低血压患者196例,其中45%规律透析,92例随机分入限制性液体组、104例分入开放性液体组。主要终点为90天内出院前全因死亡,限制性液体组显著低于开放性液体组(20例[21.7%] vs 41例[39.4%],HR 0.5,95%CI 0.29-0.85)。限制性液体组无血管升压药天数更多(19.7±10.4天 vs 15.4±12.6天;平均差4.3天,95%CI 1.0-7.5),28天内无呼吸机天数更多(21.0±11.8天 vs 16.5±13.6天;平均差4.5天,95%CI 0.9-8.1)。作者认为,在晚期CKD合并脓毒症诱导低血压患者中,早期限制性液体策略优先使用血管升压药与90天内出院前全因死亡风险更低相关。
要点
- 晚期CKD合并脓毒症诱导低血压患者中,限制性液体组90天内出院前全因死亡20例(21.7%),开放性液体组41例(39.4%),HR 0.5(95%CI 0.29-0.85)。
- 限制性液体组无血管升压药天数19.7±10.4天 vs 开放性液体组15.4±12.6天,平均差4.3天(95%CI 1.0-7.5)。
- 限制性液体组28天内无呼吸机天数21.0±11.8天 vs 开放性液体组16.5±13.6天,平均差4.5天(95%CI 0.9-8.1)。
- 该分析纳入晚期CKD定义:eGFR<30 mL/min/1.73 m2或终末期肾病规律透析,45%患者规律透析。
适用人群与场景
- 晚期CKD患者,定义为eGFR<30 mL/min/1.73 m2或终末期肾病规律透析,合并脓毒症诱导低血压,来源于CLOVERS试验人群。
- 196例中45%为规律透析患者,92例随机分入限制性液体组、104例分入开放性液体组。
诊断标准与关键阈值
- 晚期CKD定义:eGFR<30 mL/min/1.73 m2或终末期肾病规律透析。
研究设计与关键结果
- 研究类型:CLOVERS试验的事后分析,纳入196例晚期CKD合并脓毒症诱导低血压患者。
- 干预与对照:早期限制性液体策略(优先使用血管升压药) vs 早期开放性液体策略。
- 主要终点:90天内出院前全因死亡,限制性液体组20例(21.7%) vs 开放性液体组41例(39.4%),HR 0.5(95%CI 0.29-0.85)。
- 次要终点:无血管升压药天数限制性液体组19.7±10.4天 vs 开放性液体组15.4±12.6天,平均差4.3天(95%CI 1.0-7.5);28天内无呼吸机天数限制性液体组21.0±11.8天 vs 开放性液体组16.5±13.6天,平均差4.5天(95%CI 0.9-8.1)。
证据类型、等级与局限
- 证据类型:CLOVERS试验(NCT03434028,2018-02-09,BioLINCC 14149)的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在晚期CKD合并脓毒症诱导低血压患者中,早期限制性液体策略优先使用血管升压药与90天内出院前全因死亡风险更低相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Early fluid management in patients with advanced chronic kidney disease (CKD) and sepsis-induced hypotension is challenging with limited evidence to support treatment recommendations. We aimed to compare an early restrictive versus liberal fluid management for sepsis-induced hypotension in patients with advanced CKD.
METHODS: This post-hoc analysis included patients with advanced CKD (eGFR of less than 30 mL/min/1.73 m2 or history of end-stage renal disease on chronic dialysis) from the crystalloid liberal or vasopressor early resuscitation in sepsis (CLOVERS) trial. The primary endpoint was death from any cause before discharge home by day 90.
RESULTS: Of 1563 participants enrolled in the CLOVERS trial, 196 participants had advanced CKD (45% on chronic dialysis), with 92 participants randomly assigned to the restrictive treatment group and 104 assigned to the liberal fluid group. Death from any cause before discharge home by day 90 occurred significantly less often in the restrictive fluid group compared with the liberal fluid group (20 [21.7%] vs. 41 [39.4%], HR 0.5, 95% CI 0.29-0.85). Participants in the restrictive fluid group had more vasopressor-free days (19.7 ± 10.4 days vs. 15.4 ± 12.6 days; mean difference 4.3 days, 95% CI, 1.0-7.5) and ventilator-free days by day 28 (21.0 ± 11.8 vs. 16.5 ± 13.6 days; mean difference 4.5 days, 95% CI, 0.9-8.1).
CONCLUSIONS: In patients with advanced CKD and sepsis-induced hypotension, an early restrictive fluid strategy, prioritizing vasopressor use, was associated with a lower risk of death from any cause before discharge home by day 90 as compared with an early liberal fluid strategy.
TRIAL REGISTRATION: NCT03434028 (2018-02-09), BioLINCC 14149.
参考来源
- Jorda A, Douglas IS, Staudinger T, et al. Fluid management for sepsis-induced hypotension in patients with advanced chronic kidney disease: a secondary analysis of the CLOVERS trial. Crit Care. 2024. PMID: 38992663. doi:10.1186/s13054-024-05019-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。